V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240007955 | 240004903 | 1.75 | 54.6 | Disease modification (D) | null | 2016-03-19 | Docetaxel | N | N | 240035220 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240007956 | 240004903 | null | 79 | null | 2017-08-21 | 2017-09-04 | CHLVPP | N | null | 240035220 | CISPLATIN + TOPOTECAN |
| 240007957 | 240004903 | 1.67 | 61.3 | Curative (C) | null | 2017-11-03 | IDELALISIB + RITUXIMAB | 02 | N | 240035220 | CAPECITABINE |
| 240007958 | 240004904 | 1.72 | 51 | Curative (C) | 2014-12-22 | 2014-12-28 | CISPLATIN + FLUOROURACIL + RT | 02 | N | 240035238 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240007959 | 240004905 | null | null | Curative (C) | 2014-11-08 | 2014-11-09 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | N | N | 240035243 | LENALIDOMIDE |
| 240007960 | 240004906 | 1.53 | 77.5 | Palliative (P) | null | 2014-01-17 | Bortezomib + Cyclophos + Dex | N | N | 240035247 | BEVACIZUMAB |
| 240007961 | 240010720 | 1.7 | 67.2 | Palliative (P) | 2014-12-16 | 2014-12-22 | ECX | N | N | 240035250 | BEVACIZUMAB |
| 240007962 | 240004907 | null | 58 | null | 2015-03-18 | 2015-03-18 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 2 | N | 240035255 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240007963 | 240010721 | 1.6 | null | Curative (C) | 2014-05-07 | 2014-05-07 | DHAP - R | 01 | N | 240035258 | BEACOPP |
| 240007964 | 240010721 | 1.47 | 61.1 | Curative (C) | 2014-09-19 | 2014-09-20 | CISPLATIN + FLUOROURACIL + RT | null | N | 240035258 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240007965 | 240010721 | 1.72 | 79.5 | Neo-adjuvant (N) | 2017-10-30 | 2017-10-30 | CHOEP - 14 days | 02 | N | 240035258 | FCR |
| 240007966 | 240010721 | 1.75 | null | Palliative (P) | 2015-11-25 | 2015-11-25 | Cytarabine Low Dose | 02 | N | 240035258 | RAVVA TRIAL |
| 240007967 | 240010721 | 1.66 | 47 | Palliative (P) | 2014-10-11 | 2014-10-15 | CISPLATIN + FLUOROURACIL + RT | N | N | 240035258 | AML18 TRIAL |
| 240007968 | 240004908 | 0 | 63.85 | Palliative (P) | 2016-06-06 | 2016-06-06 | Bevacizumab 15mg/kg | 02 | null | 240035270 | CISPLATIN + FLUOROURACIL + RT |
| 240007969 | 240004908 | 1.75 | 90.6 | null | null | 2015-09-29 | RUXOLITINIB | N | N | 240035270 | CLADRIBINE |
| 240007970 | 240004908 | 0 | 66 | Curative (C) | null | 2014-05-18 | CISPLATIN + VINORELBINE | N | Y | 240035270 | DHAP - R |
| 240007971 | 240004908 | 1.81 | 73.3 | Disease modification (D) | 2015-10-05 | 2015-10-13 | IDARUBICIN | N | N | 240035270 | METHOTREXATE INTRATHECAL |
| 240007972 | 240004908 | 1.71 | null | Curative (C) | 2013-10-26 | 2013-11-23 | Abiraterone | null | N | 240035270 | CHLORAMBUCIL + OBINUTUZUMAB |
| 240007973 | 240004909 | 1.88 | null | Curative (C) | 2017-08-07 | 2017-08-07 | CETUXIMAB | 02 | null | 240035282 | ALEMTUZUMAB |
| 240007974 | 240010723 | null | 56.2 | Curative (C) | 2014-05-07 | 2014-05-26 | CVP | N | N | 240035287 | R-EPOCH |
| 240007975 | 240004910 | 1.43 | 78 | Palliative (P) | 2013-02-07 | 2013-02-14 | Cisplatin + Etoposide + RT | 01 | N | 240035292 | CLADRIBINE |
| 240007976 | 240004910 | 1.75 | 120.8 | Neo-adjuvant (N) | 2014-10-08 | 2014-10-12 | IBRUTINIB | N | N | 240035292 | FLAG |
| 240007977 | 240004911 | 1.77 | 87.9 | Palliative (P) | 2014-04-08 | 2014-04-11 | Bortezomib +/- Dexamethasone | 02 | N | 240035296 | ENZALUTAMIDE |
| 240007978 | 240010725 | 0 | 101 | Palliative (P) | 2014-10-30 | 2014-11-01 | CARBOPLATIN + FLUOROURACIL | 02 | N | 240035298 | IBRUTINIB |
| 240007979 | 240010725 | null | 103.7 | Palliative (P) | 2018-03-06 | 2018-03-10 | CHOP-R + CYTARABINE HIGH DOSE | 2 | N | 240035298 | METHOTREXATE INTRATHECAL |
| 240007980 | 240010725 | 0 | 75 | Curative (C) | 2016-09-24 | 2016-10-12 | LENALIDOMIDE | N | N | 240035298 | CYTARABINE |
| 240007981 | 240015656 | 1.52 | 50.8 | Palliative (P) | 2013-06-04 | 2013-06-04 | FLAIR Trial | N | N | 240035304 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 240007982 | 240015656 | 1.66 | 81.9 | Palliative (P) | 2013-04-22 | 2013-04-22 | Cisplatin + Paclitaxel | N | N | 240035304 | ENRICH TRIAL |
| 240007983 | 240015656 | 1.71 | 0 | Curative (C) | 2017-01-11 | 2017-02-11 | R-EPOCH | 2 | null | 240035304 | FCR |
| 240007984 | 240004912 | 1.52 | null | null | 2016-08-04 | 2016-09-06 | IPILIMUMAB + NIVOLUMAB | N | N | 240035320 | PARAGON TRIAL |
| 240007985 | 240004913 | null | null | Curative (C) | null | 2018-03-20 | CYCLOPHOSPHAMIDE | 99 | null | 240035322 | ACCEPT TRIAL |
| 240007986 | 240004914 | 1.63 | 70.4 | Curative (C) | 2016-03-13 | 2016-03-22 | RCEOP | 02 | N | 240035325 | CVP |
| 240007987 | 240004914 | 1.68 | 75 | Palliative (P) | 2014-11-19 | 2015-01-26 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | null | 240035325 | CAPECITABINE |
| 240007988 | 240004915 | null | null | Curative (C) | 2013-06-13 | 2013-06-14 | Cytarabine HD + Methotrexate HD | 02 | N | 240035341 | FLAG |
| 240007989 | 240004915 | 1.53 | 40.9 | Palliative (P) | 2015-01-24 | 2016-03-24 | Cisplatin + Etoposide (3 day) | N | N | 240035341 | BEVACIZUMAB |
| 240007990 | 240004915 | 0 | 144.9 | Palliative (P) | 2014-07-01 | 2014-07-29 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 02 | N | 240035341 | R-EPOCH |
| 240007991 | 240004916 | null | 58 | Neo-adjuvant (N) | 2018-06-20 | 2018-11-21 | ABVD | N | N | 240035348 | CAPECITABINE |
| 240007992 | 240004917 | null | 58.65 | Disease modification (D) | null | 2014-07-27 | GDP | N | null | 240035349 | BRENTUXIMAB |
| 240007993 | 240004918 | 1.65 | 72 | Palliative (P) | 2016-07-24 | 2016-07-31 | CYCLOPHOSPHAMIDE + RITUXIMAB + Dexamethasone | null | null | 240035354 | CYCLOPHOSPHAMIDE |
| 240007994 | 240004918 | 1.8 | 68 | Palliative (P) | 2013-03-23 | 2013-12-08 | R-EPOCH | N | N | 240035354 | ENZALUTAMIDE |
| 240007995 | 240004919 | 1.57 | 69.9 | Curative (C) | 2017-11-12 | 2017-12-13 | Bevacizumab 15mg/kg | 02 | N | 240035357 | CYCLO + RITUXIMAB + VINCRISTINE |
| 240007996 | 240004919 | 1.54 | 55 | Palliative (P) | 2013-03-11 | 2013-03-13 | CHOEP - 21 days | 2 | N | 240035357 | R-EPOCH |
| 240007997 | 240004920 | null | 67 | Disease modification (D) | 2015-01-06 | 2015-01-08 | AML 19 TRIAL | N | N | 240035364 | CYCLOPHOSPHAMIDE |
| 240007998 | 240004921 | 1.62 | 67.4 | Curative (C) | 2014-01-02 | 2014-01-10 | ECHELON-2 TRIAL | N | N | 240035365 | IDARUBICIN + MERCAPTOPURINE + METHOTREXATE + VINCRISTINE |
| 240007999 | 240004922 | 1.67 | 58.8 | Not known (9) | 2017-07-03 | 2017-07-12 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 2 | N | 240035366 | FEC |
| 240008000 | 240010730 | null | null | Palliative (P) | 2015-06-23 | 2015-06-24 | Cytarabine Low Dose | N | null | 240035369 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 240008001 | 240004923 | null | 80 | Palliative (P) | 2016-10-04 | 2016-10-08 | CHOEP - 14 days | N | N | 240035370 | FCR |
| 240008002 | 240004924 | 1.83 | 69.4 | Palliative (P) | 2018-10-28 | 2018-10-29 | EOX | N | N | 240035371 | PILOT TRIAL |
| 240008003 | 240004925 | 1.58 | null | Curative (C) | 2014-05-24 | 2014-05-24 | Cisplatin + Vinorelbine (IV) | 02 | N | 240035372 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINBLASTINE |
| 240008004 | 240004926 | 1.71 | 76.4 | Curative (C) | null | 2014-05-26 | Bevacizumab 15mg/kg | N | N | 240035378 | CISPLATIN + TOPOTECAN |